These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 33439984)

  • 1. Increased O-GlcNAcylation prevents degeneration of dopamine neurons.
    Hart GW; Huang CW
    Brain; 2020 Dec; 143(12):3515-3518. PubMed ID: 33439984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. O-GlcNAcylation regulates dopamine neuron function, survival and degeneration in Parkinson disease.
    Lee BE; Kim HY; Kim HJ; Jeong H; Kim BG; Lee HE; Lee J; Kim HB; Lee SE; Yang YR; Yi EC; Hanover JA; Myung K; Suh PG; Kwon T; Kim JI
    Brain; 2020 Dec; 143(12):3699-3716. PubMed ID: 33300544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LRRK2 phosphorylation of auxilin mediates synaptic defects in dopaminergic neurons from patients with Parkinson's disease.
    Nguyen M; Krainc D
    Proc Natl Acad Sci U S A; 2018 May; 115(21):5576-5581. PubMed ID: 29735704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein kinase D1 (PKD1) phosphorylation promotes dopaminergic neuronal survival during 6-OHDA-induced oxidative stress.
    Asaithambi A; Ay M; Jin H; Gosh A; Anantharam V; Kanthasamy A; Kanthasamy AG
    PLoS One; 2014; 9(5):e96947. PubMed ID: 24806360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy.
    Graham DL; Gray AJ; Joyce JA; Yu D; O'Moore J; Carlson GA; Shearman MS; Dellovade TL; Hering H
    Neuropharmacology; 2014 Apr; 79():307-13. PubMed ID: 24326295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for an imbalance between tau O-GlcNAcylation and phosphorylation in the hippocampus of a mouse model of Alzheimer's disease.
    Gatta E; Lefebvre T; Gaetani S; dos Santos M; Marrocco J; Mir AM; Cassano T; Maccari S; Nicoletti F; Mairesse J
    Pharmacol Res; 2016 Mar; 105():186-97. PubMed ID: 26816085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression.
    Liu G; Sgobio C; Gu X; Sun L; Lin X; Yu J; Parisiadou L; Xie C; Sastry N; Ding J; Lohr KM; Miller GW; Mateo Y; Lovinger DM; Cai H
    Hum Mol Genet; 2015 Sep; 24(18):5299-312. PubMed ID: 26123485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant PINK1 upregulates tyrosine hydroxylase and dopamine levels, leading to vulnerability of dopaminergic neurons.
    Zhou ZD; Refai FS; Xie SP; Ng SH; Chan CH; Ho PG; Zhang XD; Lim TM; Tan EK
    Free Radic Biol Med; 2014 Mar; 68():220-33. PubMed ID: 24374372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A tango for two: Dopamine and α-synuclein synergy may explain nigrostriatal degeneration in Parkinson's disease.
    Chen V; Saez-Atienzar S
    Mov Disord; 2018 Feb; 33(2):249. PubMed ID: 29356152
    [No Abstract]   [Full Text] [Related]  

  • 10. Dopamine transporter glycosylation correlates with the vulnerability of midbrain dopaminergic cells in Parkinson's disease.
    Afonso-Oramas D; Cruz-Muros I; Alvarez de la Rosa D; Abreu P; Giráldez T; Castro-Hernández J; Salas-Hernández J; Lanciego JL; Rodríguez M; González-Hernández T
    Neurobiol Dis; 2009 Dec; 36(3):494-508. PubMed ID: 19766189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are Dopamine Oxidation Metabolites Involved in the Loss of Dopaminergic Neurons in the Nigrostriatal System in Parkinson's Disease?
    Herrera A; Muñoz P; Steinbusch HWM; Segura-Aguilar J
    ACS Chem Neurosci; 2017 Apr; 8(4):702-711. PubMed ID: 28233992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The emerging link between O-GlcNAcylation and neurological disorders.
    Ma X; Li H; He Y; Hao J
    Cell Mol Life Sci; 2017 Oct; 74(20):3667-3686. PubMed ID: 28534084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The importance of choosing a preclinical model that reflects what happens in Parkinson's disease.
    Segura-Aguilar J
    Neurochem Int; 2019 Jun; 126():203-209. PubMed ID: 30922924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alteration in the progression of dopamine neuron degeneration: may caffeine offer new perspective?
    Morelli M; Frau L; Simola N
    Exp Neurol; 2012 Sep; 237(1):218-22. PubMed ID: 22705384
    [No Abstract]   [Full Text] [Related]  

  • 15. The necroptosis machinery mediates axonal degeneration in a model of Parkinson disease.
    Oñate M; Catenaccio A; Salvadores N; Saquel C; Martinez A; Moreno-Gonzalez I; Gamez N; Soto P; Soto C; Hetz C; Court FA
    Cell Death Differ; 2020 Apr; 27(4):1169-1185. PubMed ID: 31591470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurotensin-polyplex-mediated brain-derived neurotrophic factor gene delivery into nigral dopamine neurons prevents nigrostriatal degeneration in a rat model of early Parkinson's disease.
    Hernandez-Chan NG; Bannon MJ; Orozco-Barrios CE; Escobedo L; Zamudio S; De la Cruz F; Gongora-Alfaro JL; Armendáriz-Borunda J; Reyes-Corona D; Espadas-Alvarez AJ; Flores-Martínez YM; Ayala-Davila J; Hernandez-Gutierrez ME; Pavón L; García-Villegas R; Nadella R; Martinez-Fong D
    J Biomed Sci; 2015 Jul; 22(1):59. PubMed ID: 26198255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Altered dopamine metabolism and its role in pathogenesis of Parkinson's disease].
    Wang XR; Zhu SX; Wen XM; Xie JX; Song N
    Sheng Li Xue Bao; 2021 Feb; 73(1):89-102. PubMed ID: 33665664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Make dopamine neurons great again: An exciting new therapeutic option in parkinson's disease.
    Bonet-Ponce L; Singleton AB
    Mov Disord; 2017 Aug; 32(8):1164. PubMed ID: 28631854
    [No Abstract]   [Full Text] [Related]  

  • 19. O-GlcNAcylation regulates ischemia-induced neuronal apoptosis through AKT signaling.
    Shi J; Gu JH; Dai CL; Gu J; Jin X; Sun J; Iqbal K; Liu F; Gong CX
    Sci Rep; 2015 Sep; 5():14500. PubMed ID: 26412745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron, Dopamine, and α-Synuclein Interactions in at-Risk Dopaminergic Neurons in Parkinson's Disease.
    Song N; Xie J
    Neurosci Bull; 2018 Apr; 34(2):382-384. PubMed ID: 29380248
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.